The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks
Open accessAbstract
Alzheimer’s disease (AD) is the most common chronic neurodegenerative disease worldwide. It causes cognitive dysfunction, such as aphasia and agnosia, and mental symptoms, such as behavioral abnormalities; all of which place a significant psychological and economic burden on the patients’ families. No specific drugs are currently available for the treatment of AD, and the current drugs for AD only delay disease onset and progression. The pathophysiological basis of AD involves abnormal deposition of beta-amyloid protein (Aβ), abnormal tau protein phosphorylation, decreased activity of acetylcholine content, glutamate toxicity, autophagy, inflammatory reactions, mitochondria-targeting, and multi-targets. The US Food and Drug Administration (FDA) has approved five drugs for clinical use: tacrine, donepezil, carbalatine, galantamine, memantine, and lecanemab. We have focused on the newer drugs that have undergone clinical trials, most of which have not been successful as a result of excessive clinical side effects or poor efficacy. Although aducanumab received rapid approval from the FDA on 7 June 2021, its long-term safety and tolerability require further monitoring and confirmation. In this literature review, we aimed to explore the possible pathophysiological mechanisms underlying the occurrence and development of AD. We focused on anti-Aβ and anti-tau drugs, mitochondria-targeting and multi-targets, commercially available drugs, bottlenecks encountered in drug development, and the possible targets and therapeutic strategies for future drug development. We hope to present new concepts and methods for future drug therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“However, in two Phase III trials (NCT00575055 and NCT00574132), bapineuzumab did not significantly improve cognitive function in patients with AD (Salloway et al., 2014).”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1×
“Donanemab was associated with ARIA-related AEs during the trial (Mintun et al., 2021; Rashad et al., 2022; Shcherbinin et al., 2022).”
BackgroundA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“These findings could provide new insights into the prevention and treatment of AD at an early stage (Honig et al., 2018; Liu-Seifert et al., 2018).”
BackgroundYao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940 · cited 1×
“The activity and expression of the mitochondrial respiratory chain (mRC) decreased in early AD and its animal model (Yao et al., 2009).”
BackgroundSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 4×
“Bapineuzumab also causes amyloid-related imaging abnormalities (ARIA) with effusion or edema (ARIA-E) and ferriflavin deposition (Salloway et al., 2018).”
BackgroundInfluentialHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723 · cited 1×
“, 2019), neurovascular mechanism and mitochondrial hypothesis (Reddy and Reddy, 2017; Shevtsova et al., 2017, 2021; Wilkins and Morris, 2017; Liu et al., 2019), as well as “multi-target” agents (Makhaeva et al.”
BackgroundA Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · cited 1×
“Tideglusib, a thiadiazolone that irreversibly inhibits GSK-3β and reduces tau phosphorylation, did not show any clinical benefit in a double-blind, placebo-controlled Phase II trial demonstrating the clinical efficacy of GSK-3 inhibitors in AD and is subject to further study (Lovestone et al., 2015).”
BackgroundTranslocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506 · cited 1×
“Translocator protein density has been used as a biomarker for neuroinflammation in AD (Chen and Guilarte, 2008).”
MethodAmyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
Reddy, P. H., & Oliver, D. M. (2019) · Cells · doi:10.3390/cells8050488 · Cited by 496
Cited by
Zhang, Y., Tang, C., He, Y., Zhang, Y., Li, Q., Zhang, T., Zhao, B., Tong, A., Zhong, Q., & Zhong, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117540 · Cited by 36
Metadata
- Authors
- Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2023-08-03
- Volume
- 15
- Pages
- 1206572-1206572
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W4385549041
- Cited by
- 165
- References
- 40
- FWCI
- 23.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks. https://app.cochat.ai/papers/10.3389/fnagi.2023.1206572
- The paper
- Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S. (2023). Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2023.1206572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.